Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals

Journal of Viral Hepatitis Apr 16, 2018

Cho H, et al. - Researchers determined whether or not high-potency Nucleos(t)ide analogues (NAs) (entecavir and tenofovir disoproxil fumarate [TDF]) reduce the risk of tumour recurrence more potently than low-potency NAs after curative treatment of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). They noted that antiviral agents with high genetic barrier to resistance (entecavir and TDF) reduced the risk of HCC recurrence compared with other antivirals and no antiviral...
Go to Original

General Internal Medicine Gastroenterology Hematology/Oncology Infectious Disease Clinical Pharmacology

Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.